Share
218 Posts.
lightbulb Created with Sketch. 43
clock Created with Sketch. 27/08/21
19:52
Share
Originally posted by Pharmargeddon:
↑
This has been sitting under our collective noses since February.synthetic with high specificity and affinity to the FGF5 protein. The research program high affinity (Kd 0.118 – 0.7of binding to FGF5, and high specificity, showing no binding activity with closely related FGF family members or the FGFR1 receptor. The aptamers were subsequentlyThe no binding with FGF7 ( a close family member) may allow the FGF5 inhibitor to get on with its work without negating the new growth efforts of FGF7 which may have its own set of likes for optimum growth which do not include any inhibitors, thank you very much
Expand
Thanks for drawing attention to this again Pharma - it points to an interesting development. The one query I have however is if the company wants shareholders to grasp its significance why is the announcement written in gobbledygook? Blinded by science is fine, but not to your shareholders surely.
(20min delay)